Preferential Rights Issue / Företrädesemission 2018

Alzinova carried out a preferential rights issue of SEK 30.1 million before costs, together with a directed rights issue of SEK 15.0 million before costs, to finance the clinical development program of ALZ-101. Below you will find information in regards to this issue and the prospectus.